DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Trelstar (Triptorelin Pamoate) - Summary



TRELSTAR™ DEPOT contains a pamoate salt of triptorelin, and triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH or GnRH) with greater potency than the naturally occurring LHRH.

TRELSTAR™ DEPOT is indicated in the palliative treatment of advanced prostate cancer. It offers an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.

See all Trelstar indications & dosage >>


Media Articles Related to Trelstar (Triptorelin)

Promising drug combination for advanced prostate cancer
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.11.26]
A new drug combination may be effective in treating men with metastatic prostate cancer.

Long-term T Does Not Up Risk for High-grade Prostate Cancer
Source: Medscape Hematology-Oncology Headlines [2015.11.25]
The use of testosterone replacement therapy for up to 5 years is not associated with a subsequent increased risk of being diagnosed with high-grade prostate cancer.
Medscape Medical News

Football strengthens the bones of men with prostate cancer
Source: Bones / Orthopedics News From Medical News Today [2015.11.24]
Men with prostate cancer run the risk of brittle bones as a side-effect of their treatment.

New Model for Prostate Cancer Screening Reduces Biopsies
Source: Medscape Hematology-Oncology Headlines [2015.11.23]
A new testing algorithm has been validated as a way to reduce the number of unnecessary biopsies among men screened for prostate cancer without compromising detection of high-risk disease.
Medscape Medical News

Yoga may benefit men with prostate cancer, study finds
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2015.11.21]
Men receiving radiation therapy for prostate cancer may find twice-weekly yoga sessions can help maintain life quality and alleviate some side effects, new research suggests.

more news >>

Published Studies Related to Trelstar (Triptorelin)

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. [2011.07.20]
CONTEXT: Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available. OBJECTIVE: To determine the effect of the temporary ovarian suppression obtained by administering the gonadotropin-releasing hormone analogue triptorelin during chemotherapy on the incidence of early menopause in young patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy... CONCLUSION: The use of triptorelin-induced temporary ovarian suppression during chemotherapy in premenopausal patients with early-stage breast cancer reduced the occurrence of chemotherapy-induced early menopause. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00311636.

A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. [2011.07]
PURPOSE: To compare the role of an aromatase inhibitor (letrozole) with a GnRH agonist (triptorelin) versus case control on the pregnancy rate and recurrence of symptoms and signs in patients with endometriosis... CONCLUSION: Pregnancy rate and endometriosis recurrence rate are comparable among the 3 groups.

Synchronization of ovulation and fertility in weaned sows treated with intravaginal triptorelin is influenced by timing of administration and follicle size. [2011.01.15]
A 100 mug dose of triptorelin was tested for synchronizing ovulation in sows. In Experiment 1, conducted in April through June, sows (n = 125) were assigned to Control (untreated), TG-96 (Triptorelin Gel (TG) given intravaginally at 96 h post-weaning), or TG-E (given intravaginally at estrus)... However, ovulation induction and timed AI success may benefit from an approach that ensures sows have adequate follicle development at time of treatment.

A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2010.01]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.

A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2009.01.08]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.Rapid onset of action and avoidance of initial gonadotropin flare with an aromatase inhibitor may be advantageous for short-term management of women with myomas of any size who are to be managed transiently and who wish to avoid surgical intervention, specifically women with unexplained infertility having uterine myoma.

more studies >>

Clinical Trials Related to Trelstar (Triptorelin)

Comparative Study of Long-acting and Short Acting Triptorelin in PCOS Patients Who Underwent IVF/ICSI [Recruiting]
To test whether long-acting Triptorelin on pituitary down-regulation can improve the clinical pregnancy rate and reduces the incidence of ovarian hyperstimulation syndrome (OHSS) in infertile high-risk patients with polycystic ovaries (PCOs) who underwent in vitro fertilization (IVF) or Intracytoplasmic sperm injection

Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer [Terminated]
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as triptorelin, may protect normal ovarian cells from the side effects of chemotherapy. PURPOSE: This randomized phase II trial is studying how well triptorelin works in preserving ovarian function in premenopausal women who are receiving chemotherapy for early-stage breast cancer.

Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls [Active, not recruiting]
The aim of the study is to determine the specificity, sensitivity and diagnostic efficiency of the Triptorelin Test in the assessment of CPP compared to GnRH test as gold standard. Hypothesis: Aqueous Triptorelin Acetate is so efficient as GnRH to CPP assessment. Study population are girls with suspicious clinical features of precocious puberty

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty [Completed]
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22. 5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The null hypothesis of the study is that the proportion of patients achieving luteinizing hormone (LH) suppression to prepubertal levels at Month 6 is 80%.

Triptorelin for Ovary Protection in Childhood Onset Lupus [Completed]
The purpose of this study is to test the safety of triptorelin when used for the protection of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for systemic lupus erythematosus (SLE; lupus) and to see what effects (good or bad) it has on patients. The study will be done with female patients who have been diagnosed with systemic lupus erythematosus, are younger than 21 years of age, and require intravenous cyclophosphamide to control the disease. Each patient will be in the study for approximately 23 months, until 4 months after the intravenous cyclophosphamide treatment has been completed. This study is currently being conducted at 3 sites across the United States and Brazil (Los Angeles, Cincinnati and San Paulo Brazil). A total of 50 patients will participate in this study. Each patient will be randomized (assigned) to one of 5 groups. Randomization means that patients are put into a group completely by chance. It is like flipping a coin. Neither the patient nor the study staff knows what group the patient is in. The patient has a 20% chance of being placed in any group. Funding Source: FDA OOPD and Watson Pharmaceuticals

more trials >>

Reports of Suspected Trelstar (Triptorelin) Side Effects

Death (4)Depression (4)Fatigue (3)Hospitalisation (3)Hot Flush (3)Fracture (3)Rash (3)Initial Insomnia (2)Vitamin D Deficiency (2)Pruritus (2)more >>

Page last updated: 2015-11-26

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015